TAK Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
XNYS
20.27
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
TAK
$20.27
—
Key stats
$20.27
- 52-Week Range
- $12.99 – $20.36
- YTD
- +29.77%
- IV Rank (30D)
- 63.94
- Straddle Price
- $1.80
- P/C Vol Ratio
- 3.10
- Market Cap
- $63.7B
- Open
- $20.18
- Day Range
- $20.08 – $20.36
- Volume
- 2,002,864
- Prev Close
- $19.93
Fair Value
MODEL: NEUTRAL
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.15% |
| Beta vs SPY | 0.48 |
| Cost of Equity (CAPM) | 7.54% (VRP-adj) |
| WACC | 7.57% |
| Volatility Risk Premium | +124.5pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Quality Score | 0/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $18.48 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $18.76 |
| Bollinger Width / SMA20 | 75.7% (drives anchor stability) |
| Net Debt | $0.0B |
Peers used for multiples: BMY, GSK, LLY, MRK, NVO, NVS, PFE, TEVA
60-Day Conviction
8%
20-Day Fair Value
≈ by Nov 20, 2026
$20.42
α +0.5%
rank 36%
conviction
36%
40-Day Fair Value
≈ by Dec 21, 2026
$20.54
α +1.1%
rank 36%
conviction
36%
60-Day Fair Value
≈ by Jan 19, 2027
$20.27
α -0.2%
rank 36%
conviction
8%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | $6.99 | 0% | |
| Peer P/E | n/a | 0% | median 43.0× · 6 peers |
| Peer EV/EBITDA | n/a | 0% | median 19.1× · 6 peers |
| Peer P/B | n/a | 0% | median 5.9× · 6 peers |
| Peer P/S | n/a | 0% | median 4.1× · 6 peers |
| Market Anchor (SMA50) | $18.48 | 100% | stability 71% (BB-width) |
| Options Expected (B-L 30d) | $19.27 | 0% | 6 strikes · skew -1.12 |
As of 2026-10-22 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNYS
- Market Cap
- $63.7B
- Employees
- 47,029
- List Date
- 2008-03-07
- CIK
- 0001395064
- Next Earnings
- 2026-10-29 (Pre-Market)
- EPS Forecast
- $0.31 (1 est.)
- Homepage
- https://www.takeda.com
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -2.00% | 4.86% | 0.25% | 1.81% | 1.06% | 10.31% | 2.71% |
| Feb | -5.86% | 4.25% | -3.15% | 1.46% | 8.75% | 7.20% | 2.11% |
| Mar | 7.54% | -4.91% | 7.85% | -4.60% | 0.20% | 0.43% | 1.08% |
| Apr | -10.41% | 0.21% | 0.42% | -4.32% | 2.62% | -11.13% | -3.77% |
| May | 1.48% | -0.55% | -4.81% | 1.21% | 0.00% | -3.97% | -1.11% |
| Jun | 0.96% | -0.99% | -1.13% | -3.14% | 2.52% | 5.53% | 0.62% |
| Jul | -2.37% | 3.69% | -2.43% | 6.77% | -10.74% | 7.25% | 0.36% |
| Aug | -0.90% | -3.98% | 1.85% | 7.51% | 5.86% | 6.83% | 2.86% |
| Sep | -3.13% | -5.60% | 0.52% | -4.69% | -3.43% | -0.22% | -2.76% |
| Oct | -14.51% | 1.30% | -10.99% | -2.38% | -8.82% | 13.72%* | -3.61% |
| Nov | -6.45% | 10.92% | 3.66% | -2.44% | 7.45% | -- | 2.63% |
| Dec | 3.49% | 4.91% | 0.71% | -4.47% | 7.81% | -- | 2.49% |
| Total | -29.36% | 13.64% | -8.14% | -8.00% | 11.66% | 39.05% | 3.14% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $18.85
SMA 50: $18.54
SMA 200: $17.43
Current: $20.31
EMA 12: $19.41
EMA 26: $18.97
MACD: 0.4442 | Signal: 0.1701
BULLISH
ADX (14): 31.06
TREND
+DI: 44.45
−DI: 12.09
Momentum Oscillators
RSI (14): 72.70
OVERBOUGHT
Stoch %K: 95.92
Stoch %D: 93.19
Williams %R: -1.72
Volume & Volatility
BB Upper: $20.34
BB Lower: $17.36
NEUTRAL
OBV: 117,926,393
Vol SMA 20: 2,732,669
Vol ROC: -42.95%
ATR: $0.34
True Range: $0.43
HV 20: 23.0%
HV 30: 21.1%
HV 60: 21.7%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-23T00:00:00 – 2026-10-21T00:00:00
AI Analysis
LLM Stock Analysis Report for TAK
Executive Summary
Overall Assessment: NEUTRAL (6/10)
Key drivers: Recent news headlines, technical momentum signals, and options market activity.
Primary risks: Regulatory verdict, high implied volatility.
Investment thesis: Takeda's recent news on AI-drugs and stem cell therapy has sparked interest in the company. However, the regulatory verdict against the company may impact sentiment. The options market is pricing a potential move of $1.58 by expiration, which could be driven by news headlines or technical signals.
Recent news sentiment impact: Positive sentiment from AI-drug and stem cell therapy news, offset by negative regulatory verdict.
Technical Analysis
Trend Direction: Short-term (1-4 weeks): Bullish; Medium-term (1-3 months): Neutral; Long-term (3-12 months): Bearish
Support/Resistance Levels:
- Lower band: $15.10
- Middle band: $16.07
- Upper band: $17.03
- Critical price level: $16.39 (EMA 12)
Momentum Signals:
- RSI: 57.75 (neutral)
- MACD: Bullish crossover
- Bollinger Bands: Neutral
Volume Analysis:
- Volume SMA 20: 2651545.10
- On-Balance Volume (OBV): 81106442.04
- Volume Rate of Change: -47.53%
News & Sentiment Analysis
Recent Headlines Summary: Positive news on AI-drugs and stem cell therapy, offset by negative regulatory verdict.
Sentiment Assessment: Neutral (average sentiment from recent headlines)
Catalyst Identification: Upcoming earnings report and potential regulatory developments.
Market Narrative: The company's recent news has generated interest, but the regulatory verdict may impact sentiment. Technical signals are mixed, with a short-term bullish trend and medium-term neutrality.
Risk & Volatility Assessment
Beta Interpretation: Low risk relative to market (beta 0.28)
Volatility Regime: Low volatility - stock moves less than market
Options Market Signals:
- IV Rank: 12.0% (Low)
- Current IV: 57.9%
- Expected Move: $1.58 (42 DTE), 7-DTE: $0.88
- Volume Flow: 106 calls vs 3 puts
- Open Interest: 119 calls vs 4 puts
Downside Protection: Support levels at $15.10 and $16.07, with a critical price level at $16.39 (EMA 12).
Market Context & Positioning
Sector Performance: Relative strength within the pharmaceutical sector
Institutional Activity: Mixed institutional interest signals
Correlation Analysis: Low correlation to market (R-squared interpretation)
Relative Valuation: Position within a trading range, with recent news driving price movements.
Key Levels & Action Items
Critical Price Levels:
- Support levels at $15.10 and $16.07
- Critical price level at $16.39 (EMA 12)
- Resistance level at $17.03 (upper band)
Breakout/Breakdown Levels: Technical levels that could trigger significant moves:
- Short-term bullish trend: Break above $17.03 or below $15.10
- Medium-term neutrality: Consolidation around $16.07 or further consolidation
Time-Sensitive Catalysts: Earnings report and potential regulatory developments.
Risk Management: Stop-loss levels at $15.10 and $16.07, with position sizing considerations based on risk tolerance.
Note: Please review the entire report before drawing any investment conclusions. The analysis is based solely on publicly available data and should not be taken as personalized investment advice.
Generated
News
All TAK news →
TAK Options Activity & IV Rank
TAK IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 38.2%
7-DTE IV: —
Expected Move: $1.80
7-DTE Move: $1.80
Days to Exp: 29 (2026-11-20)
Options Flow
Call Volume: 10
Put Volume: 31
P/C Volume: 3.1
BEARISH
Call OI: 102
Put OI: 541
P/C OI: 5.304
Total OI: 643
ATM Options Pricing
ATM Call: $0.82
ATM Put: $0.97
Call %: 4.1%
Put %: 4.8%
Chain Summary
Chain Volume: 404
Chain OI: 2,593
Last Updated: 10/22/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 26th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
26%
vs own history
GEX tilt
+0.12
OI-weighted, today
Vanna tilt
+0.05
δ-sensitivity to IV
Charm tilt
-0.65
δ-decay vs time
Charm tilt -0.65: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 7 ATM contracts, 1k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
ATM 39.2% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)63.9MediumOct 22
Straddle Price (30 DTE)$1.80Oct 22
Beta Analysis
Risk Metrics
Beta: 0.1126
Alpha: 37.07%
Correlation: 0.0669
R-Squared: 0.4%
Stock Volatility: 21.5%
Market Volatility: 12.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own TAK
5 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $41.2M | #406 of 3138 | -14.1% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $16.8M | #1231 of 3716 | new | 13F | |
| Citadel Hedge fund Ken Griffin | $2.7M | #2610 of 6285 | -73.1% | 13F | |
| Point72 Hedge fund Steve Cohen | $1.2M | #1421 of 1945 | new | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $280K | #2419 of 4729 | -13.9% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
TAK Institutional Ownership (13F)
Latest filings — 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
5 filers$26.37M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Jane Street Group, LLC Custodian | $12.33M | 46.75% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $12.17M | 46.13% | 2026-06-30 |
| 3 | Walleye Trading LLC | $993.86K | 3.77% | 2026-06-30 |
| 4 | Walleye Capital LLC | $609.14K | 2.31% | 2026-06-30 |
| 5 | Susquehanna International Group, LLP Custodian | $274.11K | 1.04% | 2026-06-30 |
2 filers$492.12K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Walleye Trading LLC | $488.92K | 99.35% | 2026-06-30 |
| 2 | Walleye Capital LLC | $3.21K | 0.65% | 2026-06-30 |
TAK Insider Trading (Form 4)
Latest: 2026-09-15Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-15 | Lauren Rusckowski Duprey | Chief Transformation Officer | Sell (S) | −34,535 | $18.54 | -$640.3K | EDGAR |
| 2026-09-03 | Andrew Stewart Plump | President, R&D | Sell (S) | −116,191 | $18.49 | -$2.15M | EDGAR |
| 2026-08-21 | Andrew Stewart Plump | President, R&D | Sell (S) | −19,651 | $18.49 | -$363.3K | EDGAR |
| 2026-08-19 | Nicola Deidre Petal Greenway | Chief Human Resources Officer | Sell (S) | −12,980 | $18.11 | -$235.1K | EDGAR |
| 2026-08-12 | Gabriele Ricci | Chief Data & Tech. Officer | Sell (S) | −25,088 | $17.10 | -$429.0K | EDGAR |
| 2026-08-12 | Nicola Deidre Petal Greenway | Chief Human Resources Officer | Sell (S) | −6,774 | $17.10 | -$115.8K | EDGAR |
| 2026-08-12 | Julie So-Young Kim | President and CEO | Sell (S) | −89,090 | $17.10 | -$1.52M | EDGAR |
| 2026-08-12 | Teresa Marie Bitetti | President, OBU | Sell (S) | −50,012 | $17.10 | -$855.2K | EDGAR |
| 2026-08-12 | Giles Richard Platford | President, IBU | Sell (S) | −31,083 | $17.10 | -$531.5K | EDGAR |
| 2026-08-12 | Andrew Stewart Plump | President, R&D | Sell (S) | −165,393 | $17.10 | -$2.83M | EDGAR |
| 2026-08-12 | Lauren Rusckowski Duprey | Chief Transformation Officer | Sell (S) | −47,586 | $17.10 | -$813.7K | EDGAR |
| 2026-08-12 | Nicola Deidre Petal Greenway | Chief Human Resources Officer | Sell (S) | −34,603 | $17.51 | -$605.8K | EDGAR |
| 2026-08-12 | Elaine Mary Shannon | Pres., Global Supply & Quality | Sell (S) | −20,363 | $17.55 | -$357.4K | EDGAR |
| 2026-08-12 | Ramy Riad Ahmed Ibrahim | President, PDT BU | Sell (S) | −7,277 | $17.10 | -$124.4K | EDGAR |
| 2026-08-12 | Awny Samaan Botros Farajallah | Chief Medical Officer | Sell (S) | −14,006 | $17.10 | -$239.5K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
TAK Insider Holdings
25 insiders · @ $20.31
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Christophe Pierre Weber | President and CEO | 1,014,200 | $20.60M | $0 | 1 | 2026-04-28 |
| 2 | Andrew Stewart Plump | President, R&D | 912,034 | $18.52M | -$5.34M | 5 | 2026-09-03 |
| 3 | Julie So-Young Kim | President and CEO | 391,489 | $7.95M | -$1.52M | 3 | 2026-08-12 |
| 4 | Giles Richard Platford | President, IBU | 315,838 | $6.41M | -$531.5K | 3 | 2026-08-12 |
| 5 | Teresa Marie Bitetti | President, OBU | 252,010 | $5.12M | -$855.2K | 3 | 2026-08-12 |
| 6 | Natalie Anne Marie Furney | Global General Counsel | 204,298 | $4.15M | -$527.8K | 2 | 2026-08-12 |
| 7 | Lauren Rusckowski Duprey | Chief Transformation Officer | 191,522 | $3.89M | -$1.45M | 4 | 2026-09-15 |
| 8 | Rhonda Janice Pacheco | President, U.S. Business Unit | 182,507 | $3.71M | -$289.0K | 2 | 2026-08-12 |
| 9 | Agosti Marcello Pignagnoli | Head, Strat. & Port. Dev | 176,977 | $3.59M | -$392.6K | 3 | 2026-08-12 |
| 10 | Gabriele Ricci | Chief Data & Tech. Officer | 171,654 | $3.49M | -$429.0K | 3 | 2026-08-12 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ETF Holders
16 ETFs hold TAK
16 shown · $87.07M total exposure · 0.11% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | FVD First Trust Value Line® Dividend Index Fund | First Trust | 0.43% | $34.1M | $7.9B | 2026-10-20 |
| 2 | PPH VanEck Pharmaceutical ETF | VanEck | 2.82% | $30.4M | $1.1B | 2026-10-20 |
| 3 | AVDE Avantis International Equity ETF | Avantis | 0.06% | $11.3M | $19.5B | 2026-10-20 |
| 4 | APIE ActivePassive International Equity ETF | Nport | 0.26% | $2.7M | — | 2026-05-31 |
| 5 | VEU Vanguard FTSE All-World Ex-US ETF | Vanguard | 0.00% | $2.2M | — | 2026-09-30 |
| 6 | BDYN iShares Dynamic Equity Active ETF | iShares (BlackRock) | 0.06% | $1.8M | $3.1B | 2026-10-20 |
| 7 | JSTC Adasina Social Justice All Cap Global ETF | Nport | 0.33% | $1.1M | — | 2026-05-31 |
| 8 | BFLX iShares Flexible Equity Active ETF | iShares (BlackRock) | 0.04% | $969,402 | $2.2B | 2026-10-20 |
| 9 | AADR AdvisorShares Dorsey Wright ADR ETF | Nport | 2.19% | $912,588 | — | 2026-06-30 |
| 10 | GINX SGI Enhanced Global Income ETF | Nport | 0.80% | $759,744 | — | 2026-05-31 |
| 11 | AVSD Avantis Responsible International Equity ETF | Avantis | 0.07% | $244,876 | $367.6M | 2026-10-20 |
| 12 | GPT Intelligent Alpha Atlas ETF | Nport | 0.64% | $151,307 | — | 2026-06-30 |
| 13 | DFIC Dimensional International Core Equity 2 ETF | Dimensional | 0.00% | $140,560 | $15.4B | 2026-10-20 |
| 14 | DFAX Dimensional World ex US Core Equity 2 ETF | Dimensional | 0.00% | $105,701 | $12.3B | 2026-10-20 |
| 15 | AVNC Avantis All International Core Equity ETF | Avantis | 0.09% | $91,444 | $97.0M | 2026-10-20 |
| 16 | FENI Fidelity Enhanced International ETF | Fidelity | 0.00% | $3,092 | $11.6B | 2026-10-20 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
—
TTM Revenue
—
TTM Net Income
—
TTM Op. Cash Flow
—
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
2.92M
SI % of Float
0.09%
Days to Cover
1.19
Short Vol Ratio
26.4%
Free Float
—
Float %
—
Short interest 2026-09-30 • Short volume 2026-10-21